be utilized provided that the concentration is adequate to dissolve the particular compound of formulas a e higher molarities may be used to provide concentrates that may be diluted prior to 1v administration or to prepare other dosage forms the amount of the compound of formulas a e is dependent on the ultimate use of the product it has been found that in the case of the citrate concentrations of 5mg ml and greater of ammonium trichloro dioxoethylene 0 0 39 tellurate may be solubilized according to the present invention this is in contrast to the phosphate buffer pbs from which only about 200 mcg ml of ammonium trichloro dioxoethylene 0 0 39 tellurate can be solubilized it is preferred to employ the aqueous solution of the complex directly without recovering and redissolving the complex the complex is stable when frozen or at refrigerated room or elevated temperatures the compounds of the invention may be administered to mammals for treatment of cancer immune deficiencies autoimmune diseases and infectious diseases using amounts that are effective in each condition the treatment will alleviate the symptoms of these diseases by causing the mammalian body to produce increased amounts of lymphokines the invention also includes the in vitro production of increased amounts of cytokines such as lymphokines and or their receptors and the use of these materials as therapeutic agents to be administered to mammals for the alleviation of cancer immune deficiences and infectious diseases it is contemplated that the composition of the invention may be used in combination with other anti.